title: Comparison of alendronate and raloxifene for the management of primary hyperparathyroidism.
abstract: OBJECTIVE
  To evaluate and compare the efficacy of alendronate sodium (ALN) and raloxifene (RLX) for the management of primary hyperparathyroidism (PHPT) in postmenopausal female patients (pts) with osteoporosis.
  
  
  METHODS
  Twenty-four postmenopausal women with osteoporosis who were diagnosed with PHPT, but refused the option of surgery, were enrolled. Participants were sequentially randomized into two groups: an ALN-group of 12 pts (70 mg/week) and a RLX-group of 12 pts (60 mg/day). The control group consisted of 10 pts with PHPT who did not have any indications for surgery.
  
  
  RESULTS
  The decrease in ionized calcium levels was significantly more pronounced in the ALN group compared to the RLX and control groups (p<0.001). In terms of difference from baseline in bone mineral density (BMD) of the lumbar area in percentages over a period of 12 months, pts in the ALN and RLX groups both showed statistically significant improvements compared to pts in the control group (control vs ALN, p<0.001; control vs RLX, p<0.001). BMD measurements of the femoral and radial areas were comparable in all three groups.
  
  
  CONCLUSIONS
  ALN and RLX may improve bone density in the lumbar area of osteoporotic post-menopausal women with PHPT. The more significant decrease in serum calcium levels which was observed in the ALN group compared to both RLX and control groups, suggests that ALN could be used for the short-term control of calcium levels in patients awaiting surgery.
authors.affiliation: Ministry of Health, Mugla Sıtkı Kocman University Research and Training Hospital, Endocrinology and Metabolism Diseases Clinic, Aydın Yolu Bulvarı, Menteşe Evleri, Nil Sitesi, F Blok No 6, Mugla, Turkey. gulhanakcil@yahoo.com.tr.
authors.forename: G
authors.initials: G
authors.lastname: Akbaba
authors.forename: S
authors.initials: S
authors.lastname: Isik
authors.forename: Y
authors.initials: Y
authors.lastname: Ates Tutuncu
authors.forename: U
authors.initials: U
authors.lastname: Ozuguz
authors.forename: D
authors.initials: D
authors.lastname: Berker
authors.forename: S
authors.initials: S
authors.lastname: Guler
mesh_terms: D000368:Aged; D019386:Alendronate / Q000627:therapeutic use*; D015519:Bone Density / Q000187:drug effects; D050071:Bone Density Conservation Agents / Q000627:therapeutic use*; D002118:Calcium / Q000097:blood; D005260:Female; D006801:Humans; D049950:Hyperparathyroidism, Primary / Q000188:drug therapy*; D008159:Lumbar Vertebrae / Q000187:drug effects; D008875:Middle Aged; D015663:Osteoporosis, Postmenopausal / Q000188:drug therapy*; D020849:Raloxifene Hydrochloride / Q000627:therapeutic use*
chemical_list: D050071:Bone Density Conservation Agents; D020849:Raloxifene Hydrochloride; D002118:Calcium; D019386:Alendronate